|
|||||
|
|
Nano-curcumin therapy,a promising method in modulating inflammatory cytokines in COVID-19 patients |
|
| Affiliation: | 1. Tuberculosis and Lung Disease Research Center of Tabriz University of Medical Sciences, Tabriz, Iran;2. Department of Internal Medicine, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran;3. Student’s Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran;4. Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran;5. Department of propaedeutics of dental diseases, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;6. Department of Family Medicine, Yassawi International Kazakh-Turkish University Hospital, Turkistan, Kazakhstan;7. Department of Surgery, Mousavi Hospital, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran;8. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran;9. Cancer Gene Therapy Research Center (CGRC), Zanjan University of Medical Sciences, Zanjan, Iran |
| Abstract: | BackgroundAs an ongoing worldwide health issue, Coronavirus disease 2019 (COVID–19) has been causing serious complications, including pneumonia, acute respiratory distress syndrome (ARDS), and multi-organ failure. However, there is no decisive treatment approach available for this disorder, which is primarily attributed to the large amount of inflammatory cytokine production. We aimed to identify the effects of Nano-curcumin on the modulation of inflammatory cytokines in COVID-19 patients.MethodForty COVID-19 patients and 40 healthy controls were recruited and evaluated for inflammatory cytokine expression and secretion. Subsequently, COVID-19 patients were divided into two groups: 20 patients receiving Nano-curcumin and 20 patients as the placebo group. The mRNA expression and cytokine secretion levels of IL-1β, IL-6, TNF-α and IL‐18 were assessed by Real‐time PCR and ELISA, respectively.ResultOur primary results indicated that the mRNA expression and cytokine secretion of IL-1β, IL-6, TNF-α, and IL-18 were increased significantly in COVID-19 patients compared with healthy control group. After treatment with Nano-curcumin, a significant decrease in IL-6 expression and secretion in serum and in supernatant (P = 0.0003, 0.0038, and 0.0001, respectively) and IL-1β gene expression and secretion level in serum and supernatant (P = 0.0017, 0.0082, and 0.0041, respectively) was observed. However, IL-18 mRNA expression and TNF-α concentration were not influenced by Nano-curcumin.ConclusionNano-curcumin, as an anti-inflammatory herbal based agent, may be able to modulate the increased rate of inflammatory cytokines especially IL-1β and IL-6 mRNA expression and cytokine secretion in COVID-19 patients, which may cause an improvement in clinical manifestation and overall recovery. |
| Keywords: | COVID-19 Nano-curcumin Cytokine storm IL-1β IL-6 ARDS"} {"#name":"keyword" "$":{"id":"k0035"} "$$":[{"#name":"text" "_":"acute respiratory distress syndrome COVID-19"} {"#name":"keyword" "$":{"id":"k0045"} "$$":[{"#name":"text" "_":"Coronavirus disease 2019 SARS-CoV"} {"#name":"keyword" "$":{"id":"k0055"} "$$":[{"#name":"text" "_":"severe acute respiratory syndrome-CoV MERS-CoV"} {"#name":"keyword" "$":{"id":"k0065"} "$$":[{"#name":"text" "_":"middle east respiratory syndrome-CoV PBMCs"} {"#name":"keyword" "$":{"id":"k0075"} "$$":[{"#name":"text" "_":"peripheral blood mononuclear cells ICU"} {"#name":"keyword" "$":{"id":"k0085"} "$$":[{"#name":"text" "_":"intensive care unit IL-1β"} {"#name":"keyword" "$":{"id":"k0095"} "$$":[{"#name":"text" "_":"Interleukin-1 β IL-6"} {"#name":"keyword" "$":{"id":"k0105"} "$$":[{"#name":"text" "_":"Interleukin-6 IL-7"} {"#name":"keyword" "$":{"id":"k0115"} "$$":[{"#name":"text" "_":"Interleukin_7 IL-8"} {"#name":"keyword" "$":{"id":"k0125"} "$$":[{"#name":"text" "_":"Interleukin-8 IL-18"} {"#name":"keyword" "$":{"id":"k0135"} "$$":[{"#name":"text" "_":"Interleukin-18 TNF-α"} {"#name":"keyword" "$":{"id":"k0145"} "$$":[{"#name":"text" "_":"tumor necrosis factor-alpha MCP-1"} {"#name":"keyword" "$":{"id":"k0155"} "$$":[{"#name":"text" "_":"monocyte chemoattractant peptide G-CSF"} {"#name":"keyword" "$":{"id":"k0165"} "$$":[{"#name":"text" "_":"granulocyte-colony stimulating factor TLR"} {"#name":"keyword" "$":{"id":"k0175"} "$$":[{"#name":"text" "_":"toll-like receptors CD80"} {"#name":"keyword" "$":{"id":"k0185"} "$$":[{"#name":"text" "_":"cluster of differentiation 80 CD86"} {"#name":"keyword" "$":{"id":"k0195"} "$$":[{"#name":"text" "_":"cluster of differentiation 86 ROS"} {"#name":"keyword" "$":{"id":"k0205"} "$$":[{"#name":"text" "_":"reactive oxygen species PCR"} {"#name":"keyword" "$":{"id":"k0215"} "$$":[{"#name":"text" "_":"polymerase chain reaction PBS"} {"#name":"keyword" "$":{"id":"k0225"} "$$":[{"#name":"text" "_":"phosphate buffered saline FCS"} {"#name":"keyword" "$":{"id":"k0235"} "$$":[{"#name":"text" "_":"fetal calf serum PMA"} {"#name":"keyword" "$":{"id":"k0245"} "$$":[{"#name":"text" "_":"phorbol myristate acetate ELISA"} {"#name":"keyword" "$":{"id":"k0255"} "$$":[{"#name":"text" "_":"enzyme-linked immunosorbent assay mRNA"} {"#name":"keyword" "$":{"id":"k0265"} "$$":[{"#name":"text" "_":"messenger RNA cDNA"} {"#name":"keyword" "$":{"id":"k0275"} "$$":[{"#name":"text" "_":"complementary DNA TMB"} {"#name":"keyword" "$":{"id":"k0285"} "$$":[{"#name":"text" "_":"tetra methyl benzidine Th1"} {"#name":"keyword" "$":{"id":"k0295"} "$$":[{"#name":"text" "_":"T-helper-1 IBD"} {"#name":"keyword" "$":{"id":"k0305"} "$$":[{"#name":"text" "_":"inflammatory bowel disease MS"} {"#name":"keyword" "$":{"id":"k0315"} "$$":[{"#name":"text" "_":"multiple sclerosis |
| 本文献已被 ScienceDirect 等数据库收录！ | |
